{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:23:39Z","timestamp":1775316219731,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41429-019-0235-3","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T02:02:38Z","timestamp":1569549758000},"page":"956-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Muraminomicins, novel ester derivatives: in vitro and in vivo antistaphylococcal activity"],"prefix":"10.1038","volume":"72","author":[{"given":"Yoshiko","family":"Kagoshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Tokumitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiko","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuka","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouki","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Konosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsufumi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"235_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C. et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u2013e55. \nhttps:\/\/doi.org\/10.1093\/cid\/ciq146\n\n.","journal-title":"Clin Infect Dis"},{"key":"235_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJM199808203390806","volume":"339","author":"FD Lowy","year":"1998","unstructured":"Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520\u201332.","journal-title":"N Engl J Med"},{"key":"235_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1086\/313597","volume":"30","author":"JW Chien","year":"2000","unstructured":"Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis. 2000;30:146\u201351.","journal-title":"Clin Infect Dis"},{"key":"235_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD. et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673\u201381.","journal-title":"Clin Infect Dis"},{"key":"235_CR5","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1345\/aph.1Q225","volume":"45","author":"MR Jorgenson","year":"2011","unstructured":"Jorgenson MR, DePestel DD, Carver PL. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2011;45:1384\u201398.","journal-title":"Ann Pharmacother"},{"key":"235_CR6","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90:269\u201381.","journal-title":"Yale J Biol Med"},{"key":"235_CR7","first-page":"391","volume":"30","author":"CN G\u00f3mez","year":"2017","unstructured":"G\u00f3mez CN, Siller RM, Mu\u00f1oz BJL. Mechanisms of resistance to daptomycin in Staphylococcus aureus. Rev Esp Quimioter. 2017;30:391\u201396.","journal-title":"Rev Esp Quimioter"},{"key":"235_CR8","first-page":"269","volume":"39","author":"R Musumeci","year":"2016","unstructured":"Musumeci R, et al. Resistance to linezolid in Staphylococcus spp. clinical isolates associated with ribosomal binding site modifications: novel mutation in domain V of 23S rRNA. New Microbiol. 2016;39:269\u201373.","journal-title":"New Microbiol"},{"key":"235_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1039\/b202149h","volume":"20","author":"K Kimura","year":"2003","unstructured":"Kimura K, Bugg TDH. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat Prod Rep. 2003;20:252\u201373.","journal-title":"Nat Prod Rep"},{"key":"235_CR10","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1128\/JB.180.23.6429-6432.1998","volume":"180","author":"DS Boyle","year":"1998","unstructured":"Boyle DS, Donachie WD. MraY is an essential gene for cell growth in Escherichia coli. J Bacteriol. 1998;180:6429\u201332.","journal-title":"J Bacteriol"},{"key":"235_CR11","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/nar\/gkf418","volume":"30","author":"JA Thanassi","year":"2002","unstructured":"Thanassi JA, Hartman-Neumann SL, Dougherty TJ, Dougherty BA, Pucci MJ. Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res. 2002;30:3152\u201362.","journal-title":"Nucleic Acids Res"},{"key":"235_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7164\/antibiotics.24.215","volume":"24","author":"A Takatsuki","year":"1971","unstructured":"Takatsuki A, Arima K. Tamura G. Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin. J Antibiot. 1971;24:215\u201323.","journal-title":"J Antibiot"},{"key":"235_CR13","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.7164\/antibiotics.38.1617","volume":"38","author":"K Isono","year":"1985","unstructured":"Isono K, et al. Liposidomycins: novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis. J Antibiot. 1985;38:1617\u201321.","journal-title":"J Antibiot"},{"key":"235_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.7164\/antibiotics.39.1047","volume":"39","author":"H Yamaguchi","year":"1986","unstructured":"Yamaguchi H, et al. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J Antibiot. 1986;39:1047\u201353.","journal-title":"J Antibiot"},{"key":"235_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.7164\/antibiotics.42.662","volume":"42","author":"M Inukai","year":"1989","unstructured":"Inukai M, et al. Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. I. Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot. 1989;42:662\u20136.","journal-title":"J Antibiot"},{"key":"235_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.7164\/antibiotics.42.506","volume":"42","author":"JP Karwowski","year":"1989","unstructured":"Karwowski JP, et al. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. I. Taxonomy of the producing organism and fermentation. J Antibiot. 1989;42:506\u201311.","journal-title":"J Antibiot"},{"key":"235_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.7164\/antibiotics.47.595","volume":"47","author":"S Chatterjee","year":"1994","unstructured":"Chatterjee S, et al. Napsamycins, new Pseudomonas active antibiotics of the mureidomycin family from Streptomyces sp. HIL Y-82,11372. J Antibiot. 1994;47:595\u20138.","journal-title":"J Antibiot"},{"key":"235_CR18","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.1021\/ja017748h","volume":"124","author":"LA McDonald","year":"2002","unstructured":"McDonald LA, et al. Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J Am Chem Soc. 2002;124:10260\u20131.","journal-title":"J Am Chem Soc"},{"key":"235_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.7164\/antibiotics.56.580","volume":"56","author":"M Igarashi","year":"2003","unstructured":"Igarashi M, et al. Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. J Antibiot. 2003;56:580\u20133.","journal-title":"J Antibiot"},{"key":"235_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/ja.2007.88","volume":"60","author":"R Murakami","year":"2007","unstructured":"Murakami R, et al. A-102395, a new inhibitor of bacterial translocase I, produced by Amycolatopsis sp. SANK 60206. J Antibiot. 2007;60:690\u20135.","journal-title":"J Antibiot"},{"key":"235_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/ja.2008.71","volume":"61","author":"R Murakami","year":"2008","unstructured":"Murakami R, et al. A-94964, a novel inhibitor of bacterial translocase I, produced by Streptomyces sp. SANK 60404. I. Taxonomy, isolation and biological activity. J Antibiot. 2008;61:537\u201344.","journal-title":"J Antibiot"},{"key":"235_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ja.2011.38","volume":"64","author":"Y Fujita","year":"2011","unstructured":"Fujita Y, et al. A-90289 A and B, new inhibitors of bacterial translocase I, produced by Streptomyces sp. SANK 60405. J Antibiot. 2011;64:495\u2013501.","journal-title":"J Antibiot"},{"key":"235_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/187152606784112128","volume":"6","author":"TD Bugg","year":"2006","unstructured":"Bugg TD, Lloyd AJ, Roper DI. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets. 2006;6:85\u2013106.","journal-title":"Infect Disord Drug Targets"},{"key":"235_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7164\/antibiotics.42.674","volume":"42","author":"F Isono","year":"1989","unstructured":"Isono F, Katayama T, Inukai M, Haneishi T. Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. III. Biological properties. J Antibiot. 1989;42:674\u20139.","journal-title":"J Antibiot"},{"key":"235_CR25","doi-asserted-by":"publisher","unstructured":"Fujita Y, et al. Muraminomicins, new lipo-nucleoside antibiotics from Streptosporangium sp. SANK 60501-structure elucidations of muraminomicins and supply of the core component for derivatization. J Antibiot. 2019. \nhttps:\/\/doi.org\/10.1038\/s41429-019-0215-7","DOI":"10.1038\/s41429-019-0215-7"},{"key":"235_CR26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0960-894X(02)00109-9","volume":"12","author":"C Dini","year":"2002","unstructured":"Dini C, et al. Synthesis of sub-micromolar inhibitors of MraY by exploring the region originally occupied by the diazepanone ring in the liposidomycin structure. Bioorg Med Chem Lett. 2002;12:1209\u201313.","journal-title":"Bioorg Med Chem Lett"},{"key":"235_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1021\/ml5000096","volume":"5","author":"Y Takeoka","year":"2014","unstructured":"Takeoka Y, et al. Expansion of antibacterial spectrum of muraymycins toward Pseudomonas aeruginosa. ACS Med Chem Lett. 2014;5:556\u201360.","journal-title":"ACS Med Chem Lett"},{"key":"235_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ja.2013.9","volume":"66","author":"Y Takahashi","year":"2013","unstructured":"Takahashi Y. et al. Novel semisynthetic antibiotics from caprazamycins A\u2013G: caprazene derivatives and their antibacterial activity. J Antibiot. 2013;66:171\u20138.","journal-title":"J Antibiot"},{"key":"235_CR29","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\u20149th ed.: Approved Standard M07-A9. Wayne, PA, USA: CLSI; 2012."},{"key":"235_CR30","unstructured":"National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline, NCCLS document M26-A. Wayne, PA, USA: NCCLS; 1999."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0235-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:32:20Z","timestamp":1684618340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-019-0235-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1038\/s41429-019-0235-3","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"8 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}